KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Evaluating Asthma Clinical Remission with Inhaled Therapy: Post Hoc Analyses of CAPTAIN.

John Oppenheimer, Ian D Pavord, Tom Corbridge, Jodie Crawford, Steven Gould, Mohamed Hamouda, Peter Howarth, Emmeline Burrows, Alison Moore, Stephen G Noorduyn, David Slade, Stephen Weng, Njira Lugogo

Adv Ther 43(2) 729-749

PMID41442024
PMCIDPMC12909358
DOI10.1007/s12325-025-03442-x
发表日期2025-12-24
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 7 张 PMC Figure,均未识别为 KM 图:Fig. 1:非 KM 图;Fig. 2:AI 判定为 flow diagram;Fig. 3:非 KM 图;Fig. 4:非 KM 图;Fig. 5:非 KM 图;另有 2 张未列出。
摘要

摘要

INTRODUCTION: Clinical remission (CR) is an emerging treatment goal in asthma. However, evidence showing whether CR is achievable with inhaled therapy is lacking. This post hoc analysis of CAPTAIN evaluated attainability of a composite CR endpoint with inhaled fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) or FF/VI. METHODS: CAPTAIN (GSK 205715) was a Phase IIIA, randomized, controlled, 24-52-week trial comparing once-daily single-inhaler FF/UMEC/VI versus FF/VI in adults with uncontrolled moderate-to-severe asthma despite ICS/LABA. CR was defined as a composite endpoint comprising no systemic corticosteroids, no severe exacerbations, ACQ-5 total score < 1.50, and either change from baseline in FEV1 ≥ 0 ml (lung function stabilization) or ≥ 100 ml (lung function optimization), assessed for patients meeting the CR endpoint at Week 24 (W24) and achieving CR at W52 with FF/UMEC/VI (100/62.5/25, 200/62.5/25 μg) versus FF/VI (100/25, 200/25 μg). Additional analyses assessed the CR endpoint at W24/W52 using ACQ-5 ≤ 0.75 and ≤ 1.00 thresholds. Adjusted odds/risk ratios for CR were calculated for W24. RESULTS: More patients met the CR endpoint (lung function stabilization/optimization) with FF/UMEC/VI versus FF/VI at W24 (stabilization: 42-47% vs 31-36%; optimization: 31-36% vs 19-26%) and W52 (stabilization: 43-47% vs 33-34%; optimization: 30-38% vs 21-24%). Using more stringent ACQ-5 thresholds, fewer patients met the CR endpoint with ACQ ≤ 0.75 versus < 1.50 across treatment arms and timepoints. The odds and probability of meeting the CR endpoint versus not meeting the CR endpoint at W24 were greater with FF/UMEC/VI versus FF/VI, regardless of FF dose. CONCLUSION: The results of this post hoc analysis demonstrate that CR is achievable with inhaled therapy in moderate-to-severe asthma and is more likely with FF/UMEC/VI than FF/VI. CR should be considered an attainable treatment goal for patients with asthma, irrespective of disease severity or treatment history. TRIAL REGISTRATION: ClinialTrials.gov identifier, NCT02924688.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(7,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Composite CR endpoint. ACQ-5 Asthma Control Questionnaire 5-item; CR clinical remission; ED emergency department; FEV 1 forced expiratory volume in 1 s; SCS systemic corticosteroid; SD standard deviation
非 KM Figure
Fig. 2Patient disposition. All doses are in μg. FF fluticasone furoate; ITT intent-to-treat; UMEC umeclidinium; VI vilanterol
非 KM Figure
Fig. 3Proportion of patients meeting the CR endpoint at Week 24 ( a ) and achieving CR at Week 52 ( b ) with FF/VI or FF/UMEC/VI. This was a post hoc exploratory analysis. All doses are in μg. Data at Week 52 were reported for patients who continued in the study for 52 weeks. Solid bars represent the CR endpoint (no SCS use, no severe exacerbations, ACQ-5 < 1.50, and stabilized or optimized lung function), including the lung function stabilization component; hatched bars represent the CR endpoint including the lung function optimization component. ACQ-5 Asthma Control Questionnaire 5-item; CR clinical remission; FEV 1 forced expiratory volume in 1 s; FF fluticasone furoate; SCS systemic corticosteroid; UMEC umeclidinium; VI vilanterol
非 KM Figure
Fig. 4Impact of varying ACQ thresholds on the proportion of patients meeting the CR endpoint at Week 24 ( a ) and achieving CR at Week 52 ( b ) with FF/VI or FF/UMEC/VI. This was a post hoc exploratory analysis. All doses are in μg. Data at Week 52 were reported for patients who continued in the study for 52 weeks. Data represent the 4-component CR endpoint including lung function optimization and varying ACQ-5 thresholds: dotted bars represent ACQ-5 ≤ 0.75; hatched bars represent ACQ-5 ≤ 1.00; solid bars represent ACQ-5 < 1.50. ACQ-5 Asthma Control Questionnaire 5-item; CR clinical remission; FF fluticasone furoate; UMEC umeclidinium; VI vilanterol
非 KM Figure
Fig. 5Risk ratios and odds ratios for meeting the CR endpoint at Week 24 after adding UMEC to FF/VI ( a ), doubling ICS dose ( b ), and simultaneously adding UMEC and doubling ICS dose ( c ). This was a post hoc exploratory analysis; p values were not adjusted for multiplicity. All doses are in μg. The composite CR endpoint was defined as no SCS use, no severe exacerbations, ACQ-5 < 1.50, and stabilized or optimized lung function. ACQ-5 Asthma Control Questionnaire 5-item; CI confidence interval; CR clinical remission; FEV 1 forced expiratory volume in 1 s; FF fluticasone furoate; ICS inhaled corticosteroid; LABA long-acting β 2 -agonist; LAMA long-acting muscarinic antagonist; NS not significant; OR odds ratio; RR risk ratio; SCS systemic corticosteroid; UMEC umeclidinium; VI vilanterol
非 KM Figure
Fig. 6Proportion of patients who achieved CR at Week 52 and who did or did not meet the CR endpoint at Week 24, with FF/VI or FF/UMEC/VI. *For patients with data available at Week 52. This was a post hoc exploratory analysis. All doses are in µg. The composite CR endpoint was defined as no SCS use, no severe exacerbations, ACQ-5 < 1.50, and optimized lung function. ACQ-5 Asthma Control Questionnaire 5-item; CR clinical remission; FF fluticasone furoate; SCS systemic corticosteroid; UMEC umeclidinium; VI vilanterol
非 KM Figure
Fig. 7Impact of each component of the CR definition on the proportion of patients meeting the CR endpoint at Week 24 and achieving CR at Week 52 with FF/VI or FF/UMEC/VI. This was a post hoc exploratory analysis. All doses are in μg. Data at Week 52 were reported for patients who continued in the study for 52 weeks. ACQ-5 Asthma Control Questionnaire 5-item; CR clinical remission; FEV 1 forced expiratory volume in 1 s; FF fluticasone furoate; SCS systemic corticosteroid; UMEC umeclidinium; VI vilanterol
非 KM Figure